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Caloric restriction is one of the most efficient ways to promote weight loss and is known to activate protective
metabolic pathways. Frequently reported with weight loss is the undesirable consequence of fat free (lean muscle)
mass loss. Weight loss diets with increased dietary protein intake are popular and may provide additional benefits
through preservation of fat free mass compared to a standard protein, high carbohydrate diet. However, the precise
mechanism by which a high protein diet may mitigate dietary weight loss induced reductions in fat free mass has
not been fully elucidated. Maintenance of fat free mass is dependent upon nutrient stimulation of protein synthesis
via the mTOR complex, although during caloric restriction a decrease (atrophy) in skeletal muscle may be driven by
a homeostatic shift favouring protein catabolism. This review evaluates the relationship between the macronutrient
composition of calorie restricted diets and weight loss using metabolic indicators. Specifically we evaluate the effect
of increased dietary protein intake and caloric restricted diets on gene expression in skeletal muscle, particularly
focusing on biosynthesis, degradation and the expression of genes in the ubiquitin-proteosome (UPP) and mTOR
signaling pathways, including MuRF-1, MAFbx/atrogin-1, mTORC1, and S6K1.
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Current primary treatment strategies for obesity (BMI
≥30 kg/m2) are to consume a low-fat (<30% of total en-
ergy) diet with reduced caloric intake and participate in
increased physical activity to create a negative energy
balance. In overweight and obese individuals, even a
modest reduction in weight (5 kg) can have significant
health benefits including improved insulin sensitivity [1]
pancreatic islet β-cell function [2], glucose homeostasis,
blood pressure [3] and markers of cellular oxidative
damage [4]. However, during lifestyle modification
induced weight loss the loss of metabolically active fat
free mass (FFM) is frequently reported as an undesirable
consequence [5]. Emerging evidence suggests a high
ratio of protein to carbohydrate in a low-fat, caloric* Correspondence: Mciver.cass@gmail.com
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reproduction in any medium, provided the orrestricted (CR) diet may mitigate FFM reductions during
weight loss through increasing muscle protein synthesis
and/or reducing protein catabolism, thereby improving
net muscle protein balance [6]. The precise mechanism
by which an increased dietary protein intake may miti-
gate weight loss induced reductions in FFM has not
been fully elucidated.
During eucaloric conditions the continual breakdown
of protein that occurs in the body’s organs and vital tis-
sues is replenished in the post-absorptive state via supply
of amino acids derived primarily from the skeletal
muscle component of FFM [7]. In turn, during fed
states, skeletal muscle proteins are replenished through
a feeding stimulated increase in muscle protein synthesis
that occurs almost exclusively due to the protein con-
stituent of the ingested food [8]. Once requirements for
adequate substrate to replenish skeletal muscle are
exceeded, the feeding induced muscle protein response
is inhibited [9]. Providing there is adequate dietaryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fed state balances the loss of muscle protein which
occurs in the post absorptive state allowing day to day
skeletal muscle mass to remain relatively constant [7,10].
However, excess nutrient intake of amino acids and
glucose, beyond the bodies requirement to maintain
homeostasis and energy production for cellular pro-
cesses, leads to insulin resistance in skeletal muscle via a
dysregulation of the insulin signaling pathway and po-
tentially promoting protein catabolism [11,12].
The FFM reduction that typically occurs during CR
weight loss also implies a negative net skeletal muscle
protein balance. There are a number of plausible
mechanisms, several of them mediated by dietary pro-
tein that may provide some explanation for the negative
net protein balance. These include an elevated rate of
breakdown of muscle protein in response to caloric re-
striction via up-regulation of protein catabolism enzymes
[13,14]; an inadequate per-meal dose of dietary protein
and subsequently reduced maximal post-meal rate of
muscle protein synthesis [8,15]; a reduced number of
meals/protein ingestions throughout the day and subse-
quently a reduced number of periods of elevated muscle
protein synthesis [16,17]; and/or a reduced rate of post-
meal muscle protein synthesis relating to the type/qual-
ity of dietary protein being ingested [18,19]. Although it
is likely an increased dietary protein intake during CR
mitigates reductions in FFM through one or more of
these mechanisms, further well controlled randomised
clinical trials are required to investigate the contributionTable 1 Change (Δ) in fat free mass (FFM), fat mass and total
from previous studies examining the effects of increased diet
(Farnsworth et al. [28]; Luscombe-Marsh et al. [65]; Noakes et





HP Diet vs SP Diet (equal% ene
from fat) 12 weeks energy
restriction





LF-HP Diet vs HF-SP Diet 12 we
energy restriction
4 weeks energy balance
Layman
et al. [29]
Healthy Obese 25 F High protein vs High Carbohyd
(similar% energy from fat)
10 weeks energy restriction
Noakes et al.
[25]
Healthy Obese 100 F HP vs SP Diet (equal% energy
from fat)
12 weeks energy restriction
Piatti et al. [31] Healthy Obese 25 F HP vs SP Diet (equal% energy
from fat)
21 days energy restriction
†Data from women only.
**Indicates a significant retention of lean mass in the HP diet group and *indicatesof each of these factors and whether an optimal dietary
configuration exists that can completely stave off FFM
loss. This review evaluates current evidence suggesting
an increased dietary protein intake during CR weight
loss may mitigate FFM reduction in overweight and
obese persons via decreased protein catabolism and im-
prove metabolic factors when compared with standard
protein, high carbohydrate, CR weight loss diets. Candi-
date mechanisms are discussed with a focus on the
ubiquitin-proteosome (UPP) and the mammalian target
of rapamycin (mTOR) signaling pathways and their asso-
ciation with CR and retention of FFM.
High protein, caloric restriction and weight loss in
humans
A high protein, CR diet is typically considered to consti-
tute ~30% daily total energy from protein, 40% from
carbohydrate and 30% from fat, with caloric intakes
~6000 kj/day (1400 kcal) for women and 7000 kj/day
(1600 kcal) for men. A standard protein or high carbo-
hydrate diet is typically comprised of ~15% daily total
energy from protein, 55% from carbohydrate and 30%
from fat.
A high protein, low fat diet compared to a high carbo-
hydrate, standard protein CR diet has been demon-
strated to result in greater weight loss [20-25] and
metabolic advantages (greater reductions in total choles-
terol and triglycerides in men [26,27] and reduced FFM
loss in women [28-31]) (Table 1). However, there are
also a number of studies that have shown no differencesbody weight ± standard error of the mean in women
ary protein intake and weight loss on body composition
al. [25]; Layman et al. [29]; Piatti et al., 1994 [31])
ΔFFM† ΔFat mass† ΔTotal body
weight†
rgy HP Diet −0.1 ± 0.3** HP Diet −6.6 ± 0.5 HP Diet −6.6 ± 0.5
SP Diet −1.5 ± 0.3 SP Diet −7.1 ± 2.0 SP Diet −7.4 ± 0.5
eks LF-HP Diet −2.2 ± 0.5* LF/HP Diet −4.3 ± 0.8 LF-HP Diet −7.8 ± 0.8
HF-SP Diet −3.1 ± 0.5 HF/SP Diet −4.8 ± 1.2 HF-SP Diet −7.9 ± 1.3
rate HP Diet −0.88 ± 0.3** HP Diet-5.6 ± 0.5 HP Diet −7.53 ± 1.4
HC Diet −1.21 ± 0.6 HC Diet-4.7 ± 0.7 HC Diet −6.96 ± 1.36
HP Diet −1.5 ± 0.3 HP Diet −5.7 ± 0.6 HP Diet −7.6 ± 0.4
SP Diet −1.8 ± 0.3 SP Diet −4.5 ± 0.5 SP Diet −6.9 ± 0.5
HP Diet −1.40 ± 0.6** HP Diet −3.2 ± 0.6 HP Diet −4.5 ± 0.4
SP Diet −3.02 ± 0.6 SP Diet −3.3 ± 0.5 SP Diet −6.4 ± 0.9
a trend.
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[22,23,35-37] when high protein CR diet regimes are
compared to a high carbohydrate diet. Further con-
founding evidence also exists with at least one study
showing a greater loss of FFM in hyperinsulinemic males
following a high protein diet compared the standard-
protein diet [38]. However, this loss was only 0.9 kg and
the authors conclude that hyperinsulinemic obese sub-
jects, in contrast to normoinsulinemic subjects, seem to
achieve better weight reduction, less decline in energy
expenditure, and normalization of insulin levels on a
high protein compared to a isocaloric high carbohydrate
diet.
An increased thermogenic effect may give high protein
diets a metabolic advantage over high carbohydrate
diets. Dietary protein has been shown to have a substan-
tially greater effect on basal thermogenesis (compared to
carbohydrate or fat) [39,40] and nitrogen turnover is
increased (indicating protein synthesis is elevated) [39].
In eucaloric studies a short term (3-month) increase in
daily protein intake significantly decreased body fat and
preserved lean mass in healthy lean participants [41].
However, long term high protein dietary intake (>1.8 g.
kg-1 day-1) in newly diagnosed insulin dependent dia-
betes mellitus (DM) and healthy lean participants was
found to increase plasma insulin concentrations and de-
crease glucose oxidation resulting in a state of insulin re-
sistance and glucose intolerance but these were small
observational studies and not controlled interventions
[42,43].
Caloric restriction and lean muscle in humans
Although studies unanimously observe favourable bene-
fits from CR for reducing body weight and fat mass, a
confounding complication is the reduction of FFM
(muscle atrophy) which is frequently reported [5,44].
FFM is the main determinant of resting metabolic rate
(RMR) [45], which suggests a decrease in FFM could
hinder the progress of weight loss and may predispose
to weight regain [46,47]. Furthermore, lost FFM is typic-
ally not fully recovered in individuals who regain weight,
predisposing them to the burden of “sarcopenic obesity”
[48]. In women, deterioration in muscle performance
has been observed as early as perimenopause, increasing
their vulnerability to sarcopenia compared to age-
matched men [49]. Loss of FFM may also have detri-
mental effects in older persons whereby accelerated
muscle loss correlates negatively with functional capacity
for independent living [50]. Skeletal muscle atrophy,
caused by an imbalance of protein synthesis and catabol-
ism, is readily apparent in conditions such as uncon-
trolled diabetes, cancer cachexia, spinal cord injury and
muscular disuse. A review of dietary protein for muscle
atrophy in cachexia by Op den Kamp et al. [51] foundthat supplementation with dietary protein (>1.5 g.kg-1
day-1) alone or in combination with exercise training
maintains or even improves muscle mass in these
patients. In addition, protein supplementation (30 g/d)
during weight maintenance has been demonstrated to
limit weight regain following weight loss [52].
The mechanisms by which an increased dietary protein
intake mitigates dietary weight loss induced reductions in
FFM, as found in some studies, may be explained by
examination of the molecular pathways involved in the
control of muscle protein synthesis (hypertrophy) and
breakdown (atrophy). Insulin-like growth factor 1 (IGF-1)
and PKB/Akt are believed to play key roles as central tar-
gets in the protein synthesis [53] and degradation path-
ways [54]. Amino acids and insulin activate muscle
protein synthesis via a complex serine-threonine protein
kinase, mammalian target of rapamycin (mTOR) signaling
pathway (Figure 1A) resulting in cellular mass growth
[55]. Nutrient overload, in particular increased fat and ele-
vated circulating amino acids, have been shown to cause
β-cell compensation and increased activation of mTOR
which can lead to insulin resistance in peripheral insulin-
responsive tissues [56]. Beyond dysregulation of glucose
homeostasis, impaired insulin signaling in muscle contri-
butes to the muscle loss observed in obesity by promoting
protein catabolism through the expression of ubiquitin
ligases and hence a possible explanation as to why high
mTOR activity in muscles of obese humans and mice does
not result in muscle hypertrophy (Reviewed in [11]). Indi-
viduals with type 2 DM may also have impaired insulin-
mediated protein synthesis [57,58] as amino acid signaling
to mTOR complex 1 (mTORC1) requires co-stimulation
with insulin [59] which generates an inhibitory feedback
loop on insulin receptor substrate proteins [56]. This is in
contrast to older adults (>65 years) whereby a blunted
muscle protein synthesis response has been observed com-
pared with young adults (<30 years) following resistance
exercise [60], indicating that older adults may have an
impaired ability to respond to a protein anabolic stimulus
resulting in acute dysregulation of this signaling pathway
[61]. A lack of nutrients (i.e. fasting and possibly CR) have
also been proposed to activate adenosine monophosphate
(AMP)-activated kinase (AMPK) and nicotinamide aden-
ine dinucleotide (NAD+)-dependent deacetylases, such as
(Sirtuin 1) SIRT1, which in turn suppresses the mTOR
pathway [62].
There is a strong indication that dysregulation of mTOR
signaling, and therefore a reduced ability to maintain pro-
tein synthesis, occurs in translation initiation, as older
subjects have lower p70 ribosomal S6 kinase 1 (p70S6K1)
phosphorylation and blunted extracellular signal-regulated
kinase 1 and 2 (ERK1/2) and mitogen-activated protein
(MAP) kinase-interacting kinase 1 (MNK1) signaling
compared to younger subjects following exercise at the
Figure 1 (See legend on next page.)
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Figure 1 A schematic representation depicting A; the protein synthesis pathway in skeletal muscle involving the mammalian target of
rapamycin complex 1 (mTORC1). Insulin, and amino acids (including leucine) initiate activation of a cascade of protein and lipid kinases
ultimately resulting in enhanced mTOR activity, facilitating the phosphorylation of S6K1 and hyper-phosphorylation of 4E-BP, resulting in
enhanced availability of eIF4E for binding eIF4G and forming an active eIF4F complex resulting in increased protein synthesis [adapted from
Layman [88], Anthony et al. [89], Drummond et al. [61], Um et al. [98] and Kimball [90,93] and B; our proposed mechanism whereby high protein
calorie restricted weight loss increases IGF-1 activating the PI3K/Akt pathway, thereby phosphorylating (P) FoxO transcription factors and down-
regulating the expression of E3 enzymes atrogin-1 and MuRF-1, leading to a reduction in protein degradation in skeletal muscle cells. PGC-1α,
SIRT1 and AMPK are also proposed to inhibit the expression of FoxO transcription factors and therefore suppress protein breakdown [adapted
from Lecker et al. [70], Bodine et al. [99], Anthony et al. [89] and Blagosklonny et al. [62]. Dashed lines indicate an interaction with an unknown
mechanism. Red lines indicate an inhibitory signal to the pathway, and C; Summarisation of protein biosynthetic and degradation events
following standard protein, high carbohydrate compared to high protein, calorie restricted weight loss.
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high-fat diets, can reduce the ability of leptin and insulin
to promote mTORC1 activity and reduce food intake [11]
indicating that diet quality may be a driving factor in our
ability to maintain protein synthesis rather than age.
Others have found no alteration of protein levels of IRS-1,
mTOR or p70S6K in obese and type 2 DM skeletal muscle
compared to age-matched lean participants, although a re-
duction in mTOR phosphorylation in obese and type 2
DM groups and reduced System L transporters, amino
acid transporter/solute carrier family 43, member 2
(LAT4) and solute carrier family 3-activator of dibasic and
neutral amino acid transport, member 2 (CD98hc) in the
type 2 DM group have been reported [64].
Numerous studies have shown that women tend to lose
less FFM (e.g. 0.1 kg compared to 1.5 kg) with high pro-
tein CR diets than with a standard protein diet (Table 1)
[28,29,31,65], although others show no significant differ-
ences in total weight loss or total fat loss between groups.
The FFM sparing ability from increased protein:carbohy-
drate ratio in a CR diet may be mediated by the effect of
protein intake on insulin secretion [66] and proteolysis
[13]. Proteolysis mainly occurs via the ubiquitin- proteo-
some pathway (UPP), which degrades both cytosolic and
nuclear proteins [67], as well as myofibrillar proteins [68],
which comprise most of the protein in adult skeletal
muscle [69]. Studies have shown during fasting and
possibly other insulin-deficient states, a reduction in pro-
tein synthesis and increased proteolysis occur through
decreased signaling by the PI3K/Akt pathway [70] as IGF-
1/insulin blocks transcriptional up-regulation of key med-
iators of skeletal muscle atrophy [54]. IGF-1/insulin also
inhibits the expression of two E3 ligases, muscle atrophy
F-box protein (MAFbx/atrogin-1) and muscle-specific
RING finger protein 1 (MuRF-1) [71].
Ubiquitin-proteosome pathway, CR and muscle protein
degradation
During CR a decrease (atrophy) in skeletal muscle may be
driven by a homeostatic shift favouring protein catabolism
which may have a significant impact on FFM retention.
Muscle protein degradation is a complex process in whichlysosomal proteases, the Ca2+− dependent proteases, the
caspases and the UPP have been implicated [72]. Autop-
hagic and proteosomal activity decline during aging and
may contribute to age-related muscle loss [73,74]. In con-
trast, evidence in rodents suggests that CR increases the
activity and effectiveness of these cellular quality control
processes through prevention of an increase in protein
carbonyl accumulation [75], delaying the age associated
increase of chymotrypsin-like activity, an indicator of pro-
teaosome activity [76]. The stimulation of proteolysis
observed during atrophy has been shown to be partly due
to the activation of the UPP [77] and therefore this path-
way may be pivotal in FFM loss during weight loss. In
rodents, CR has been shown to decrease plasma insulin
and serum IGF-1 concentrations up to 40% [78]
(reviewed in [79]), which may impact negatively on skel-
etal muscle. As IGF-1 has been shown to block transcrip-
tional up-regulation of a number of ubiquitin-ligases [54],
a decrease in circulating IGF-1 would result in up-
regulation of MAFbx/atrogin-1 and MuRF-1 in skeletal
muscle leading to increased proteolysis and hence FFM
loss. In humans, long term severe CR (1 and 6 years) did
not reduce serum IGF-1 levels. However, a reduction in
protein intake (1.67 to 0.95 g.kg-1.day-1) during CR for
3 weeks in a small number of volunteers resulted in a re-
duction in serum IGF-1 (152 ng.mL-1) [78]. A 12 week
CR high protein, high red meat diet in men also found
IGF-related peptides significantly increased total (HP
23%; HC 18%) and bioactive (HP 18%; HC 15%) IGF-1
[80] compared to a high carbohydrate (standard protein)
diet. In weight stable older, postmenopausal women an
increased dietary protein intake (30 g whey supplement/
day for 2 years) without CR significantly increased serum
IGF-1 compared to placebo [81] indicating that increased
dietary protein, through its ability to increase IGF-1 dur-
ing CR, may prevent increased proteolysis via inhibition
of up-regulation of key ubiquitin-ligases (Figure 1B).
High protein, low-carbohydrate diets are also accom-
panied by increased stimulation of glucagon and insulin
production within the endocrine pancreas, high glycogen
turnover and to some extent stimulation of gluconeo-
genesis [42,43]. Undefined insulin levels may stimulate
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factor (FoxO) resulting in cytoplasmic retention and the
repression of target gene expression [82]. Therefore a
high protein CR diet for weight loss may suppress key
regulatory elements of the UPP. Initiation of FoxO1
phosphorylation by PKB in skeletal muscle may decrease
FoxO’s ability to stimulate the expression of the ubiqui-
tin ligase (E3) enzymes MAFbx/atrogin-1 and MuRF-1
[83] which, when up-regulated, are essential for protein
degradation and hence muscle atrophy (Figure 1B). Fol-
lowing ultra-endurance exercise and exercise in combin-
ation with weight loss the amount of ubiquitin-
conjugated proteins and chymotrypsin-like activity has
been shown to be decreased [72,84]. Up-regulation of
mRNA transcripts MuRF1, F-box and C2 proteosome
subunits were also observed as were the autophagy regu-
latory proteins Atg7 and LC3B [84] indicating that during
ultra-endurance exercise cellular quality control pro-
cesses are required to possibly improve skeletal muscle
function by repairing muscle damage. Therefore we
propose that high protein, CR weight loss diets may
phosphorylate PKB/Atk and FoxO leading to suppression
of MAFbx/atrogin-1 and MuRF-1 transcription resulting
in deceleration of proteolysis that occurs during CR in
skeletal muscle (Figure 1C) resulting in a preservation of
FFM.
Dietary protein intake and protein synthesis
Recently it was shown that a short-term, isocaloric high
protein diet (10 days, >130 g/day protein) increased
whole body protein turnover and amino acid (leucine)
oxidation with no increase in muscle protein synthesis or
mitochondrial function in either young (<25 years) or
older (>70 years) participants. This indicates that higher
protein intakes may stimulate protein synthesis following
meal ingestion but may not enhance basal protein syn-
thesis. However, postabsorptive protein catabolism (both
breakdown and amino acid oxidation) was increased dur-
ing the high protein diet [85]. Little is known about
whether this occurs with high protein diets during CR.
Dairy products, which contain whey protein, are often a
key component of a high protein, low-fat diet. Whey con-
tains both angiotensin-converting enzyme (ACE) inhibi-
tor activity and a high concentration of leucine, a
branched-chain amino acid (BCAA) [86]. The inclusion
of whey protein in CR regimes may result in greater pres-
ervation of skeletal muscle and accelerated loss of adi-
pose tissue during negative energy balance [86,87]. There
is also increasing evidence to suggest that BCAA’s, par-
ticularly leucine, have a significant role in metabolic
regulation beyond their fundamental role as substrates
for protein synthesis [86,88].
The regulation of skeletal muscle protein turnover
also involves the interactions of gene transcription andtranslation and numerous pre- and post-transcriptional
modifications [61]. Leucine stimulates signal transduction
pathways that modulate mRNA translation initiation
thereby up-regulating protein synthesis [89-91]. Alpha-
ketoisocaproic acid, a leucine metabolite has been identi-
fied to stimulate the phosphorylated heat- and acid-stable
protein (PHAS-I), a recently discovered regulator of trans-
lation initiation during cell mitogenesis [92]. The action of
leucine in the insulin signaling pathway is initiated by
mTORC1 [59,93], which is activated by a variety of hor-
mones (e.g. insulin) and nutrients (e.g. amino acids) that
stimulate cell growth and proliferation, while it is
repressed by other hormones (e.g. glucocorticoids) [94].
The mTOR complex also controls important functions in
peripheral organs including muscle oxidative metabolism,
white adipose tissue differentiation, β-cell dependent insu-
lin secretion [95] and muscle autophagy [11].
Increases in amino acid concentrations stimulate mTOR
kinase activity (Figure 1A) to initiate phosphorylation of
the inhibitory eukaryotic initiation factor 4E binding pro-
tein (4E-BP1) causing it to dissociate from the eukaryotic
translational initiation factor E (eIF4E). Once dissociated,
eIF4E is available to bind with eIF4G to form an active initi-
ation complex. Leucine has been suggested to stimulate
protein synthesis in skeletal muscle through both insulin-
dependent and independent mechanisms. The insulin-
dependent mechanism is associated with signaling through
mTOR via phosphorylation of eIF4E-binding protein1 (4E-
BP1) and S6K1 [59], in contrast to the insulin-independent
effect by an unknown mechanism that may involve phos-
phorylation of eIF4G and/or its association with eIF4E [90].
However, Amino acid availability also increases intracellular
Ca2+ levels which can activate mTORC1 by means of a Ca2
+/calmodulin-mediated activation of a Class III PI 3-kinase,
human vacuolar protein sorting 34 (hVps34) [96,97], phos-
phorylating both S6K1 and 4E-BP1. As part of this mTOR
signaling cascade, IGF-1 has also been shown to activate
translation and muscle protein synthesis via tuberous scler-
osis 2/tuberin (TSC2). PKB works by phosphorylating
TSC2 at phosphorylation sites that are distinct from AMPK
phosphorylation sites [53]. This pathway has been sug-
gested to be suppressed or deactivated by caloric restriction
via the activation of AMPK and SIRT1, which also occurs
with Metformin administration (mimics CR), and possibly
deactivating the insulin/PI3K pathway [62]. To what extent
obesity causes a dysregulation of this pathway is unclear.
Less is also clear about how high protein CR weight loss
impacts on this pathway.
Conclusion
The mechanism behind the preservation of lean muscle
following high protein, CR weight loss has been proposed
to be the increased consumption of amino acids, in par-
ticular leucine, stimulating increased muscle protein
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contrast to findings in animal models, studies in humans
have found no alteration of protein levels of IRS-1, mTOR
or p70S6K in obese and type 2 DM skeletal muscle com-
pared to age-matched lean participants and CR may in
fact deactivate this pathway. Therefore stimulation of the
mTOR pathway to increase protein synthesis does not
fully explain the retention of FFM seen in high protein,
weight loss dietary intervention studies. Here we propose
that the key mechanism may involve the suppression of
regulatory elements of the UPP in skeletal muscle to pre-
vent atrophy. As a reduction of FFM appears to be a con-
founding complication to weight loss, understanding the
underlying biological mechanisms that occur in response
to macronutrient composition may help us to provide
more comprehensive dietary information for health care
providers and individuals to facilitate healthy weight loss
and long term weight maintenance for the treatment of
obesity.
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